Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients

British Journal of Clinical Pharmacology

Volumn 64, Issue 3, 2007, Pages 353-362

  Solas, Caroline ^a,c   Simon, Nicolas ^a   Drogoul, Marie Pierre ^b   Quaranta, Sylvie ^c   Frixon Marin, Véronique ^b   Bourgarel Rey, Véronique ^c   Brunet, Corinne ^d   Gastaut, Jean Albert ^b   Durand, Alain ^a   Lacarelle, Bruno ^a,c   Poizot Martin, Isabelle ^b  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c CNRS   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

Author keywords

CYP3A5; Indinavir; MDR1; P glycoprotein; Pharmacokinetics; Single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450 3A5; GLYCOPROTEIN P; INDINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; RITONAVIR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPARTMENT MODEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RITONAVIR;

EID: 34548036943     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02903.x     Document Type: Article

References (49)

1. Molla A, Granneman GR, Sun E, Kempf DJ. Recent developments in HIV protease inhibitor therapy. Antiviral Res 1998 39 : 1 23.
2. Slain D, Pakyz A, Israel DS, Monroe S, Polk RE. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000 20 : 898 907.
3. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997 32 : 194 209.
4. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999 36 : 289 304.
5. Fröhlich M, Hoffmann MM, Burhenne J, Mikus G, Weiss J, Haefeli WE. Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br J Clin Pharmacol 2004 58 : 443 4.
6. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet 2001 27 : 383 91.
7. Washington C, Duran GE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998 19 : 203 9.
8. Lee C, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998 37 : 3594 601.
9. Kim R, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998 101 : 289 94.
10. Choo E, Leake B, Wandel C, Imamura H, Wood AJJ, Wilkinson GR, Kim RB. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000 28 : 655 60.
11. van der Sandt I, Vos CMP, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, Breimer DD. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 2001 15 : 483 91.
12. Huisman M, Smit JW, Wiltshire HR, Hoetelmans RMW, Beijnen JH, Schinkel AH. P-Glycoprotein limits oral bioavailability, brain and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001 59 : 806 13.
13. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, Back DJ. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 2001 15 : 1353 8.
14. Li L, Amidon GL, Kim JS, Heimbach T, Kesisoglou F, Topliss JT, Fleisher D. Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. J Pharmacol Exp Ther 2002 301 : 586 93.
15. Xie H, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004 5 : 243 72.
16. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004 75 : 13 33.
17. Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000 97 : 3473 8.
18. Kim R, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG. Identification of functionally variant MDR1 alleles among Americans and African Americans. Clin Pharmacol Ther 2001 70 : 189 99.
19. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001 358 : 383 4.
20. Oselin K, Gerloff T, Mrozikiewicz PM, Pähkla R, Roots I. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol 2003 17 : 463 9.
21. Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism. G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 2003 65 : 1843 52.
22. Hitzl M, Drescher S, van der Kuip H, Schaeffeler E, Fischer J, Schwab M, Eichelbaum M, Fromm MF. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001 11 : 293 8.
23. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJD. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003 13 : 89 95.
24. Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Büchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004 75 : 422 33.
25. Johne A, Köpke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, Eichelbaum M, Brockmöller J, Cascorbi I, Roots I. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002 72 : 584 94.
26. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Chaib Eddour D, Malaise J, Lison D, Squifflet JP, Wallemacq P. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004 14 : 147 54.
27. Hesselink D, van Shaik RHN, van der Heiden IP, van der Werf M, Smak Gregoor PJH, Lindemans J, Weimar W, van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003 74 : 245 54.
28. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler A, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmöller J, Halpert JR, Zanger UM, Wojnowski L. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001 11 : 773 9.
29. Lee S, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW, Goldstein JA. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003 13 : 461 72.
30. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, for the Swiss HIV, Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002 359 : 30 6.
31. Solas C, Basso S, Poizot-Martin I, Ravaux I, Gallais H, Gastaut JA, Durand A, Lacarelle B. High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr 2002 29 : 374 7.
32. Jayewardene A, Zhu F, Aweeka FT, Gambertoglio JG. Simple high-performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma. J Chromatogr B 1998 707 : 203 11.
33. Boeckmann A, Scheiner L, Beal S. NONMEM Users Guide - Part V. San Francisco : University of California, 1994.
34. Karlsson M, Jonsson EN, Wiltse CG, Wade JR. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 1998 26 : 207 46.
35. Quaranta S, Chevalier D, Bourgarel-Rey V, Allorge D, Solas C, Lo-Guidice JM, Sampol-Manos E, Vacher-Coponat H, Moal V, Broly F, Lhermitte M, Lacarelle B. Identification by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in a French population. Toxicol Lett 2006 164 : 177 84.
36. Ameyaw M, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Tho Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DHL. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001 11 : 217 21.
37. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001 69 : 169 74.
38. Kempf D, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka J, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997 41 : 654 60.
39. Malingre M, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, Schot ME, Schellens JH. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001 20 : 1951 2.
40. Meerum Terwogt J, Malingre MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, van Tellingen O, Swart M, Schellens JH. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 1999 5 : 3379 84.
41. Drewe J, Gutmann H, Fricker G, Török M, Beglinger C, Huwyler J. HIV protease inhibitor ritonavir. a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999 57 : 1147 52.
42. Perloff M, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 2000 14 : 1287 9.
43. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C, Becquemont L. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003 58 : 809 12.
44. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, Roots O. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002 54 : 610 6.
45. Oselin K, Nowakowski-Gashaw I, Mrozikiewicz PM, Wolbergs D, Pähkla R, Roots I. Quantitative determination of MDRI mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDRI gene. Eur J Clin Invest 2003 33 : 261 7.
46. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002 72 : 572 83.
47. Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002 12 : 425 7.
48. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005 19 : 371 80.
49. Granfors M, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 2006 98 : 79 85.